Prescription digital therapeutics firm Pear Therapeutics is exploring “strategic alternate options,” together with a attainable firm sale, merger or acquisition.
In a press launch, the corporate mentioned it employed a monetary advisor to look into actions that might “maximize shareholder worth.” That features a potential sale, M&A, divestiture of property, licensing or different strategic transactions. It might additionally search extra financing.
With out a transaction, Pear mentioned it could have to reorganize, liquidate or pursue different varieties of restructuring. In a submitting with the Securities and Alternate Fee, Pear withdrew its income and working steerage for fiscal 2022 and 2023. It additionally will not maintain a fourth quarter and full 12 months earnings name.
“There isn’t any set timetable for this course of and there will be no assurance that this course of will end result within the firm pursuing a transaction or that any transaction, if pursued, shall be accomplished on enticing phrases,” the corporate mentioned in a press assertion.
THE LARGER TREND
Pear affords prescription digital therapeutics for substance use dysfunction, opioid use dysfunction and insomnia. Pear acquired FDA De Novo clearance for its substance use product, reSET, in 2017.
The corporate hit the general public markets in late 2021 by means of a merger with a particular function acquisition firm, then a well-liked technique of public exit for digital well being corporations.
However the firm’s inventory worth has typically declined since then, and an October Rock Well being report famous publicly traded digital therapeutics gamers have underperformed in contrast with different digital well being firms.
Within the third quarter, Pear reported $4.1 million in income and a $30.7 million web loss. The corporate additionally mentioned it had accredited extra layoffs, affecting 59 staff, or about 22% of Pear’s workforce on the finish of September. It had beforehand laid off 25 staff over the summer time.
Pear’s former chief business officer, Julia Strandberg, additionally just lately left the corporate to go up well being tech big Philips’ linked care enterprise.
